Rowan University Rowan Digital Works

Rowan-Virtua Research Day

28th Annual Research Day

May 2nd, 12:00 AM

Unveiling the Potential: The Role of Al-Enhanced ECG in Cardiovascular Disease Detection

Alisha Vincent Rowan University


Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

Part of the Bioethics and Medical Ethics Commons, Biomedical Informatics Commons, Cardiology Commons, Cardiovascular Diseases Commons, Diagnosis Commons, Equipment and Supplies Commons, Health Information Technology Commons, Pathological Conditions, Signs and Symptoms Commons, and the Radiology Commons

Let us know how access to this document benefits you - share your thoughts on our feedback form.

Vincent, Alisha, "Unveiling the Potential: The Role of Al-Enhanced ECG in Cardiovascular Disease Detection" (2024). *Rowan-Virtua Research Day*. 109. https://rdw.rowan.edu/stratford_research_day/2024/may2/109

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.



Unveiling the Potential: The Role of AI-Enhanced ECG in Cardiovascular

Disease Detection

Alisha Vincent (OMS - II) Rowan-Virtua School of Osteopathic Medicine

BACKGROUND

- Electrocardiogram (ECG) is a ubiquitous, cost-effective, non-invasive cardiac test
- Artificial Intelligence (AI) can transform ECG into a screening tool and predictor of cardiac and non-cardiac diseases, often in asymptomatic individuals ¹⁻⁵
- Al's application to standard ECG enables it to diagnose conditions not previously identified by ECG or to do so with greater performance than previously possible ¹⁻⁵

OBJECTIVE

This review aims to provide a comprehensive exploration of the utility of Alpowered ECG as a screening tool for early detection of a range of cardiovascular diseases such as low ejection fraction (LEF), atrial fibrillation (AF), aortic valve stenosis (AVS), and cardiac amyloidosis (CA)

METHODS

Study Selection

Inclusion/Exclusion criteria: 2018 – 2024, English, full text articles

Identification of studies via databases

Article types: Randomized control trials, clinical trials

Study Strategy

KEY WORDS	DATABASE	YEARS	DATE ACCESSED	# OF RESULTS
"AI and EKG"	Pubmed	2018-2024	12/19/2023	494
	Pubmed	2018-2024	12/19/2023	4
"Artificial Intelligence EKG, Low Ejection Fraction"	Cochrane library	2018 - 2024	12/19/2023	0
	Web of Science	2018 - 2024	12/19/2023	0
"Artificial Intelligence EKG, Atrial Fibrillation"	Pubmed	2018-2024	12/19/2023	6
	Cochrane library	2018 - 2024	12/19/2023	0
	Web of Science	2018 - 2024	12/19/2023	3
	Pubmed	2018-2024	12/19/2023	21
"Artificial Intelligence EKG, Aortic valve stenosis"	Cochrane library	2018 - 2024	12/19/2023	0
	Web of Science	2018 - 2024	12/19/2023	0
	Pubmed	2018-2024	12/19/2023	6
	Cochrane library	2018 - 2024	12/19/2023	0
"Artifical Intelligence EKG, Cardiac Amyloidosis"	Web of Science	2018 - 2024	12/19/2023	0

Records removed before (n=534) ening due to duplication, usion criteria, irrelevance (n=494) Pubmed = 531 Cochrane library = 1 Web of Science = 3 Fig 1: A PRISMAbased flow chart depicts the logic Records excluded due to Records assessed for tudy type, title, exclusion LEF, AF, AVS, and CA to choosing (n=40) conditions in the study: (n=30) articles included in this report




Table 1: Data Analyses

	Author/Group	Cardiac Disease	Sample size	Odds Ratio/Positive Predictive Value	AUC	Specificity	Sensitivity
1.	Yao X, Rushlow DR, Inselman JW, et al. 6	LEF	22641	Odds ratio: 1.32	-	-	-
2.	Rushlow DR, Croghan IT, Inselman JW, et al.	LEF	11573	Odds ratio: 1.62		-	
3.	Sun JY, Qiu Y, Guo HC, et al. ⁸	LEF	26786	-		70.50%	69.20%
4.	Noseworthy PA, Attia ZI, Behnken EM, et al.	AF	1003	Odds ratio: 4.98	-	-	
5.	Fu W, Li R. 10	AF	114	-	-	100%	88.68%
6.	Gruwez H, Barthels M, Haemers P, et al. 11	AF	142310	-	0.87	-	-
7.	Cohen-Shelly M, Attia ZI, Friedman PA, et al.	AVS	258607	-	0.87	74%	78%
8.	Elias P, Poterucha TJ, Rajaram V, et al. 13	AVS	77163	-	0.88	73%	78%
9.	Kwon JM, Lee SY, Jeon KH, et al. 14	AVS	39371	-	0.88	-	-
10.	Grogan M, Lopez-Jimenez F, Cohen-Shelly M, et al. ¹⁵	CA	2541	Positive predictive value: 0.86	0.91		-

LOW EJECTION FRACTION

- AI-powered ECG increases LEF diagnosis overall and in high likelihood cases ⁶
- Clinicians following AI recommendation are twice as likely to diagnose LEF ⁷

ATRIAL FIBRILLATION

- Al-guided screening increased AF detection compared to usual care over median 9.9 months ⁹
- Al-enhanced ECG identified paroxysmal AF during normal sinus rhythm with 78.1% accuracy ¹⁰
- Wearable AI-powered ECG recorder detects AF efficiently in various postures and after exercises ¹⁰

AORTIC VALVE STENOSIS

- False positive AI-ECG doubles risk of moderate/severe AS over 15 years ¹²
- Deep learning algorithm achieved high accuracy in detecting significant AS using 12/single-lead ECG¹⁴
- Deep learning accurately detects aortic stenosis, aortic regurgitation, and mitral valve regurgitation ¹³

CARDIAC AMYLOIDOSIS

 The AI model successfully predicted the presence of CA more than 6 months before the clinical diagnosis in 56% of cases ¹⁵

DISCUSSION

- Validation in practice
 - ✓ Success relies on clinical adoption of Al-generated recommendations
 - ✓ Comprehensive testing and seamless integration into clinical workflows are crucial
- Data sharing and privacy
 - ✓ Sharing data among institutions is essential for algorithmic validation
 - ✓ Unauthorized sharing of identified health data poses ethical concerns and threatens patient trust
- Treatment decision guidance
 - Rigorous evaluation for external validity across population is necessary
- Risk of bias perpetuation
 - Al algorithms may perpetuate bias based on existing clinical practices and outcomes
 - ✓ Mitigation strategies are required to prevent the reinforcement of healthcare disparities
- Infrastructure challenges
 - ✓ Integrating AI-ECG results into electronic health records faces significant infrastructure challenges
 - Widespread implementation necessitates technological advancements and organizational investments

FUTURE IMPLICATIONS & CONCLUSION

- Al's integration with implantable and wearable cardiovascular devices for early detection
- Determining severity and staging of cardiovascular conditions
- Al-powered ECG will enhance prognosis capabilities and facilitate continuous monitoring and enable treatment adjustments
- Identifying high-risk patients for invasive evaluation
- Clinician training is important for the successful integration of AI-ECG into medical practice
- Adding AI-ECG as part of routine check-ups or annual examinations holds potential for early detection

REFERENCES

